Clinical Trials Logo

Oncology clinical trials

View clinical trials related to Oncology.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04692389 Withdrawn - Pain Clinical Trials

Jalosome® Soothing Gel Efficacy Grade 2 or 3 Radiodermatitis.

Start date: February 1, 2021
Phase: N/A
Study type: Interventional

Testing the efficacy of the Jalosome® Soothing gel in 2 or 3 grade radiodermatitis healing in oncological patients. The investigators would like to know also the efficacy of the device on quality of life and pain.

NCT ID: NCT03166774 Withdrawn - Oncology Clinical Trials

Support of the Sexual Health in Oncology

Start date: June 6, 2016
Phase:
Study type: Observational

Implementation of sexual health support program in oncology department. This program is organized in 3 axes. One is to inform the side effects of treatment on sexual health. There is a counselling team (nurse, esthetician,sexologue..etc) to raise the subject with patient and partner . Finally, the oncologist continue during the treatment to evaluate the benefit of this program and adapt their counselling according to the needs

NCT ID: NCT02356822 Withdrawn - Oncology Clinical Trials

Sarah Cannon Outcomes Registry

Start date: December 2014
Phase:
Study type: Observational [Patient Registry]

This is an investigational multi-site outcomes registry intended to collect information about a patient's cancer care. Patients may enter the Registry at any time during the patient's current stage in the continuum of care. The registries main objectives will be to measure and evaluate the effects of patient care throughout the care continuum, resulting in the identification of the most effective treatment options. Objectives will encompass evaluations and analytics around safety, effectiveness, and improved efficiencies.

NCT ID: NCT00352950 Withdrawn - Clinical trials for Non-Small Cell Lung Cancer

Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer

Start date: March 2006
Phase: Phase 1
Study type: Interventional

To determine the dose and schedule of sirolimus when given in combination with panitumumab in adult subjects with Stage IIIB/IV NSCLC